MedTrace Logo

Pharmacometrics to Advance Novel Regimens for Drug-resistant Tuberculosis-PandrTB Tuberculosis

NCT03827811 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 625

Last updated 2022-11-04

No results posted yet for this study

Summary

PandrTB is a study of the pharmacokinetics(PK) and pharmacodynamics(PD) of bedaquiline, delamanid, clofazimine, linezolid, moxifloxacin, levofloxacin and pyrazinamide used in novel combinations to treat multidrug-resistant tuberculosis(MDR-TB).

Conditions

  • Multi-drug Resistant Tuberculosis

Sponsors & Collaborators

  • Partners in Health

    collaborator OTHER

  • Epicentre

    collaborator OTHER

  • Medecins Sans Frontieres, Netherlands

    collaborator OTHER

  • Institute of Tropical Medicine, Belgium

    collaborator OTHER

  • Interactive Research and Development

    collaborator OTHER

  • University of Cape Town

    lead OTHER

Principal Investigators

  • Helen McIlleron, PhD · University of Cape Town

Eligibility

Min Age
15 Years
Max Age
99 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2020-01-30
Primary Completion
2023-04-30
Completion
2023-04-30

Countries

  • Kazakhstan
  • Lesotho
  • Pakistan
  • Peru
  • South Africa
  • Vietnam

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03827811 on ClinicalTrials.gov